Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So basically, September/October given previous 10-K filings. It means Leo has to make a deal soon or basically maximize dilution in that timeframe as the fountain is being turned off, absent an increase in share price, given current cap.
If you can't afford to lose $4, $3, $2, $1, 50 cents...
I don't think 11 years for a preclinical really is the problem. The main problem is that Leo is a garbage CEO and foolishly destroyed shareholder value. Small trial designs coupled with pushing out P3 (arguably their best shot at the time) was poor execution. Oh the irony about $30 million being dilutive to shareholders as he just sold 8M shares at 25 cents. Give me a break.
...it needs close to 200% return just to get to $1. I'm willing to bet plenty of perma-longs have averages close to that, if not higher.
Lets try some simple math... If Aspire got shares at 25c and the price is above 25c, how are they losing money? Remember, this isn't a trick question. Just math.
Aspire is NOT losing money....
10-Q Quarterly is out.
All treasury shares are retired.
Here's your selling pressure: "From April 1, 2018 to May 9, 2018, the Company has generated additional proceeds of approximately $2.0 million under the Common Stock Purchase Agreement with Aspire Capital from the sale of approximately 8.0 million shares of its common stock."
This is going to be a waste of money:
"In early 2018, the Company approved steps to focus its efforts on clinical trials for its lead drug candidates. The Company’s office and laboratory needs have shifted from compound discovery to clinical development programs. The Company is now in the process of searching sites for its future headquarters."
Rutrow scoob.
"$75 Million Shelf Registration Statement
The Company has an effective shelf registration statement on Form S-3, registering the sale of up to $75 million of the Company’s securities. The Company filed the Form S-3 with the SEC on September 11, 2017, which included registering the shares underlying the 2017 $30 million Aspire Capital stock purchase agreement. Pursuant to the instructions to Form S-3, if the Company’s non-affiliate market capitalization as of an applicable measurement time, such as upon the filing of the Company’s Annual Report on Form 10-K, does not equal or exceed $75 million, the Company will be unable to offer and sell securities from its effective shelf registration statement on Form S-3, and the Company will have to use a registration statement for which it is eligible, such as Form S-1, to offer and sell securities."
It has been the wrong logic for years now. Years ago, he opted not to do $30M worth of dilution at considerably higher share prices because, well, it would have been too much on shareholders. Low and behold, things played out and the level of shareholder damage has certainly exceeded a one-and-done approach to do ABSSSI into P3.
The share price is 36c and we have people calling for $5-10 a share... come on. Lets see the share price hold a $1-$1.25 first before calling what appears to be crazy nonsense.
22 bagger from here folks! You heard it from Daubers.
I think you need to get well versed with best execution instead of spewing nonsense:
https://www.otcmarkets.com/learn/market-101/trading
http://finra.complinet.com/en/display/display.html?rbid=2403&element_id=10455
I'm going to believe the markets and how they work. Best bid is best bid, just like best offer is best offer--please don't try to argue it.
Ugh no, best bid is best bid. You can't fill a lower bid without first filling a higher bid. Unless the higher bid removed their order, there is no scenario where that would happen. If (and I have my doubts) what you said is actually the case and your order was skipped, you should be calling your broker. And no market maker is trolling ihub looking to game a handful of posters. Markets aren't that egocentric.
Why is it that everyone shouts manipulation instead of just coming to terms that sellers are overwhelming buyers and there is a lack of interest (rightfully so) to support the existing share price?
While I don't discount that OTC and pinksheet stocks get manipulated, it's not the case every single time. All these boards shout manipulation when the share price heads down. I hate to break it to you, but it's not a hit rate of 100% across all penny stocks.
I love the smell of monopoly money getting thrown around.
Haha, 0.41 up for bid. Keeping adding longs.
Care to wager some shares on that?
As I have said before, I hold shares. Not nearly as many as I had before, but the rest of them are in tax-deferred accounts so no benefit of tax losses. At this point it makes up so little of my overall portfolio that I can just hold on to them and watch this trainwreck unfold first hand. But of course, permabulls think that anyone that says anything negative doesn't have shares or is outright short the stock.
You can go on any penny stock board on here and find the same bullshit. The reason the share price is trending lower is 1) the PRs lack meat to generate sufficient buying interest [sorry longs that "continue to add down here", you aren't buying enough] and 2) Aspire (and perhaps Aruda) selling.
Until you get some meat on these PRs that causes buyers to step in, the share price will linger. Big pharma isn't manipulating a stock they are planning on purchasing, come on. I don't consider the SEC able to catch everything but there is no way that would fly.
I have no problem averaging up, that's what prudent investors do. Throwing good money after bad is sloppy investing. Just because something is cheap does not mean it can't get cheaper.
Assuming that's true, that's still an immaterial amount of shares to have any clout over what management does or does not do.
You CANNOT have statistically significant data at the N numbers they have in these trials. They have to be designed far larger for it to have any representative impact to a population as a whole.
"Trolls" have been right every year till now. It was CTIX/IPIX's year in 2015, 2016, and 2017... I guess when the carrot keeps moving, 2018 would be the next logical year, right?
As a shareholder, of course I am here. Just because I refuse to add does not mean I don't care for what little bit I have remaining. No point in selling for losses as I can't do anything with them parked in a tax deferred account.
Such breathtaking results, so much undervalued-ness, yet the market does not care. You're not magically seeing something the market does not... you don't think you have better insights than big pharma, do you?
"Good News" generally has a positive impact on the share price. The market does not care for PR fluff. There is no reason these last few PRs couldn't have been combined. If you have nothing material to say, say nothing. The share price is going to continue to bleed until management actually provides shareholders value. Aspire is not a good thing... it's an overhang.
Management needs to deliver. Stop the carrot dangling and actually deliver shareholder value. Why anyone wants to continue to average down here when this stock has been a persistent disappointment is beyond me.
No one knows anything. Period.
Are you looking at your chart upside down?
I hope you're not extrapolating that first postings has anything to do with when I invested in shares. I've had an ihub account since 2007 and absent my recent postings, I don't bother posting. The only reason I ever came out and started posting (which my first posts here no longer exist because they were deleted) was to call out the outrageous market cap valuations that George keeps spewing at this stage of development.
Lastly, no one is crying sour apples--simply reiterating circumstances doesn't indicate an agenda as so many permabulls would try to tack on. Case and point, exactly what you are trying to insinuate. But I guess I don't own shares and/or I'm secretly shorting a 50 cent stock. Yep, that's it. It's the same old shit on all these penny stock boards. Longs continue to think there is an agenda by every poster that doesn't look through their same rose-colored glasses and throw back koolaid. I have no doubt posters like that exist, but not everyone that disagrees with your bullish outlook has it in for the stock. Just saying.
You don't change goals when you have something that is arguably the farthest along of all of it's offerings. People say well the dilution would have been too great for a $20-30M trial... considering shares are now down to 54c compared to $4.x, the net affect was just years of pain... yes, it's all hindsight when you have a substantially higher share price and looking at things with today's price levels but it's worth mentioning that the outcome had dilution occurred at higher levels would have been far better than the position the company is in currently.
...and the B for ABSSSI is where in terms of active moves into P3? Oh that's right, money is the issue. We're just going to bench one of the most viable compounds we have for a wide net of use cases while we design smaller, more cost effective trials that have little material impact for sample representation of a population.
I'd bet against your projections all day everyday. There hasn't been a structured trial with enough sample population to prove more than PoC at this junxure. P has the largest number and we still haven't seen the results.
Like a late Friday release last Friday, and the Friday before, and the Friday before that... and.... and..... and.............
Timeout... so in your head, a CEO PRing just because of what is said (or isn't said) on a stock message board is ok? Come on.
Well, absent the P trial we are still waiting on, even though they have successfully constructed trials, they aren't "meaningful" trials. A trial designed with a small amount of people is more in line with proof of concept--not that there is anything wrong with it, but it's challenging to make substantial claims on efficacy when your sample size is in no way representative of a larger population.
How isn't this the definition of fluff? There is no new content from what we already know. The company could have said nothing and we would have been in no different of a place.
Another fluff PR, fantastic. Would sure be nice to get a meaty one...
Your statement makes no sense. You can't have capitulation without high volume...
I can't blame longs for selling... the carrot continues to be dangled here with push out and push out of expected trial results. Having said that, I've all but written off the last 16k shares I have here. If it's not fluff PRs repeating the same nonsense, it's ongoing selling pressure. For those that say the share price doesn't matter, it does. It matters precisely due to the financing we are getting Aspire (lower share price = more shares; they win regardless because it's discounted shares to market).
Don't get me wrong, I'd love to see great results from the 2b trial but can't help but feel the market is getting this one right. We shall see.
It tells nothing... every pharma exec hopes for the exact same phrase for any early clinical.
This is a pointless PR that states what we already know from the one earlier this month. Why they continue to do this and not give any meat is beyond me.